Positive Patient Stories™


Jason Burdette
Vice President - Technical Operations
Jason Burdette has over 25 years experience in the pharmaceutical industry concentrated on formulation and process development, manufacturing, supply chain management and technical operations. He brings extensive experience in new product introduction of multiple products in both the US and international markets. Mr. Burdette joins us from Eagle Pharmaceuticals where he was the VP, Supply Chain. At Eagle he was responsible for supply chain management, procurement, distribution and new product introduction. Mr. Burdette joined Eagle from Shire Pharmaceuticals where he held various positions with increasing responsibility over his 10-year tenure. Including, VP Geographic Expansion Strategy and Planning, Interim Head of Product Strategy, Product Strategy Lead for Vyvanse, Adderall, and Equasym, Global Product Director, Supply Chain for the ADHD business. He was an active member of the supply chain leadership team and the international commercial team among other key executive leadership teams. Prior to Shire Pharmaceuticals, Mr. Burdette worked with aaiPharma, Elan Pharmaceuticals, Sandoz and Mylan Pharmaceuticals.
Jeanne Jew
Senior Vice President - Business Development
Jeanne Jew joined Paratek in July 2015. Ms. Jew has more than 20 years of experience in business development, product planning and general management in the biotechnology industry. Prior to joining Paratek, Ms. Jew was Senior Vice President, Business Development of KaloBios Pharmaceutical where she was responsible for business development, strategic planning, and marketing. During her tenure at KaloBios, Ms. Jew was responsible for the execution and management of its partnership with Sanofi Pasteur, and played in key role in the IPO. From 2002-2007, Ms. Jew served as Vice President of Corporate Development of Onyx Pharmaceuticals, where she was responsible for all business development activities and commercial planning for Nexavar. Prior to Onyx Pharmaceuticals, Ms. Jew held business development positions at Coulter Pharmaceuticals and became Vice President, Business Development following the acquisition of Coulter Pharmaceutical by Corixa Corporation. Earlier in her career, Ms. Jew held business development positions at Scios, Inc. and Genentech, Inc. Ms. Jew holds a Bachelor of Arts in psychology from Wesleyan University and a Master of Business Administration from Cornell University.
Raj Padmanabhan
Vice President - Information Technology
Raj Padmanabhan is our Vice President, Information Technology (IT), facilities and space planning and has served in this position since November, 2015. With more than 20 years of experience, Mr. Padmanabhan previously served as Senior Director, IT Architecture, Quality and Processes at Cubist Pharmaceuticals, a wholly owned subsidiary of Merck. During his eight-year tenure at Cubist, Mr. Padmanabhan built Information Technology infrastructure to scale business operations and support the growth of the business including successful launch of two new anti-infective products in US and international markets and successful relaunch of two commercial products in US market. Mr. Padmanabhan led several leadership task forces to increase productivity and ensure compliance with federal regulations. Prior to Cubist, Mr. Padmanabhan was Associate Director, Business and Integration Service at Biogen where he implemented global systems to support compliance with federal regulations, improve productivity and reduce costs. Raj Padmanabhan has a Bachelor of Engineering degree in Computer science and Engineering from University of Madras and a Masters in Business Administration from Babson College.
Susan Perkins, J.D.
Vice President - Intellectual Property
Susan Perkins, J.D., prior to joining Paratek, Ms. Perkins has been sole in-house patent counsel for multiple start-up biotechnology companies, managing portfolios for clinical stage and preclinical drug candidates while building platform technology IP. Most recently, Ms. Perkins was Head of Intellectual Property at Aileron Therapeutics, a leader in Stapled Peptide therapeutics. Prior to that she led IP at Avila Therapeutics (acquired by Celgene), Syntonix Pharmaceuticals (acquired by Biogen Idec) and Leukosite (acquired by Millennium Pharmaceuticals for which Ms. Perkins continued as patent counsel). Before going in-house, Ms. Perkins was associated with the law firm of Campbell & Flores in San Diego, CA. She began as a Patent Examiner with the U.S. Patent & Trademark Office. She holds a J.D. with Honors from the George Washington University, which included an externship with the Honorable Randall Radar of the U.S. Court of Appeals for the Federal Circuit. Ms. Perkins holds an advanced degree in chemistry from the University of North Carolina, and graduated Summa Cum Laude from UMass-Amherst.
Christine R. Coyne, MBA
Vice President - Marketing
Christine Coyne joined Paratek in July 2017, to lead the commercialization of our innovative compound, Omadacycline. Christine has led marketing and sales teams at Wyeth, Endo, and other small to mid-size biopharmaceutical organizations, and comes to Paratek with an impressive record of accomplishment, having overseen the successful launches of life-saving products across multiple therapeutic areas. Prior to joining us, Christine served as Vice President of Marketing, Sales, and Operations in the United States and Globally for a specialty pharmaceuticals company. She was responsible for nearly $250MM net sales across 3 commercialized products and 1 joint-venture product launch. Christine’s experience spans commoditized and orphan drug categories, large to small molecules, and products used in both primary care and hospital settings. Her proven sales and marketing skills compliment the skills of our Management Team as we plan for the successful commercialization of Omadacycline.
Sarah  Higgins
Vice President - Controller
Sarah Higgins joined Paratek in March 2015 as Controller. Throughout her career, Ms. Higgins has gained a mix of public and private accounting experience during which she developed comprehensive knowledge of generally accepted accounting principles and international financial reporting standards. Prior to joining Paratek, she spent nine years at Millennium Pharmaceuticals, Inc., now the oncology business of Takeda Pharmaceuticals, Inc., in accounting roles of increasing responsibility and scope, including financial reporting, Sarbanes-Oxley Act compliance, external audit coordination, finance system implementation, financial planning and analysis, and extensive interaction with a global finance operation. Ms. Higgins previously served as Director of Finance and Controller at Hurley of America, following six years as an audit professional with KPMG LLP. Ms. Higgins is a Certified Public Accountant and earned a Bachelor of Science in Accounting from Fairfield University.
Paul  McGovern, M.D.
Vice President - Clinical and Medical Affairs
Paul McGovern, M.D. joined Paratek in February 2017 as a Vice President of Clinical and Medical Affairs. Prior to joining Paratek, Dr. McGovern worked in Global Clinical Development at Actelion Clinical Research as a Clinical Science Program Head for cadazolid, an antibiotic in late development for Clostridium difficile infection and as an Infectious Diseases expert for other anti-infective products in development. From 2006-2013, Dr. McGovern held positions in Medical and Clinical Affairs at Wyeth and Pfizer where he worked on the tigecycline late life-cycle strategy and activities including the benefit risk. Dr. McGovern has a B.S. from the University of Notre Dame and a M.D. from Northwestern University. He completed an Internal Medicine Residency and Infectious Diseases Fellowship at the University of Pennsylvania. Following the completion of his medical training, Dr. McGovern was a faculty member at the University of Pennsylvania prior to joining Wyeth in 2006.
Steve Sandor, MBA, J.D.
Vice President - Market Access and Trade
Steve Sandor joined Paratek in July, 2017 as Vice President of Market Access and Trade. Steve has over 20 years of experience in therapeutics market access, government healthcare policy, pricing, reimbursement and account management. Steve has held various leadership roles for large U.S. and global pharmaceutical manufacturers. Prior to joining Paratek, Steve was the Vice President of Market Access and Policy at Acorda Therapeutics where he led the Payer Account Team and was responsible for pricing, contracting and payer strategy for the entire product portfolio. Before joining Acorda, he was the Vice President of Market Access and HEOR at Piramal Molecular Imaging. He was also the Global Market Access Leader for GE Healthcare, and previously the Executive Director of Managed Healthcare Marketing for Forest Laboratories, where he led a team responsible for pricing and contracting for the company’s first hospital antibiotic, and Director of Customer Planning and Contracting at Hoffmann-La Roche. Steve’s prior experience also includes ownership in a start-up specialty pharmacy where he held the position as Principal for 9 years. Steve received his undergraduate degree at the University of Maryland, Masters of Business Administration, School of Banking and Money Management at Adelphi University and his Jurist Doctorate at Elisabeth Haub School of Law at Pace University. In addition, Steve was awarded a certificate in Health Law Policy from Pace Law School and is a licensed attorney in the State of New Jersey.
Judith N. Steenbergen, PhD
Vice President, Medical Strategy and Communications
Judith Steenbergen joined Paratek in November 2015 following a distinguished career highlighted by more than a decade in clinical microbiology and antibiotic development. Judith is leading the medical strategy and KOL management for Paratek. Since the completion of her doctorate at Albert Einstein College of Medicine, she has been involved in all phases of drug development, from investigational new drug application enabling studies through antibiotic approval and commercialization. During her tenure at Cubist, she was directly involved in the development of four anti-infective agents. She has demonstrated the ability to collaborate with research leaders throughout the world and has been recognized as an expert in the clinical microbiology field. Most recently, she was instrumental in the clinical development, world-wide regulatory filings, FDA approval, and commercialization of Zerbaxa.

Talk with the Paratek Team

Send us an inquiry by submitting a form directly on the site or give us a call.